Last edition
News about Drug Discovery & Development
FDA Clears Expanded Access Programme for StemCyte's RegeneCyte Therapy in Long covid Patients
The FDA has approved an Expanded Access programme for StemCyte’s RegeneCyte, enabling eligible Long covid patients to access the cord blood-based therapy amid ongoing clinical trials.
Drug Discovery & Development | 27/01/2026 | By News Bureau | 312
ACON Launches FDA-Cleared Flowflex Plus 4-in-1 Home Test for RSV, Flu and Covid, Including Infants
Acon Laboratories has launched the first FDA-cleared 4-in-1 home test detecting RSV, Flu A, Flu B and Covid-19, approved for adults and children as young as six months.
Drug Discovery & Development | 27/01/2026 | By News Bureau | 335
BD has launched Research Cloud 7.0 globally, introducing the AI-driven Horizon Panel Maker to automate panel design, streamline workflows and enhance data quality in immunology and cancer research.
Drug Discovery & Development | 27/01/2026 | By News Bureau | 359
AGC Biologics’ Milan Cell and Gene Centre of Excellence will support the commercial rollout of Waskyra following US FDA and EU approvals, strengthening treatment options for patients with Wiskott-Aldrich syndrome.
Drug Discovery & Development | 22/01/2026 | By News Bureau | 201
CDSCO Flags 167 Drug Samples as Substandard, Seven Found Spurious
India’s drug regulator has identified 167 medicine samples that failed quality tests and classified seven additional samples as spurious during routine surveillance conducted in December. The findings were released as part of the Central Drugs Standard Control Organisation’s (CDSCO) monthly drug alert.
Drug Discovery & Development | 22/01/2026 | By Darshana | 245
China's NMPA Accepts Akeso's Gumukimab sNDa for Ankylosing Spondylitis
China’s NMPA gives approval to Akeso’s gumokimab for the treatment of active ankylosing spondylitis, supported by Phase III data showing significant symptom relief and functional improvement.
Drug Discovery & Development | 20/01/2026 | By News Bureau | 332
AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.
Drug Discovery & Development | 19/01/2026 | By News Bureau | 217
Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.
Drug Discovery & Development | 19/01/2026 | By News Bureau | 283
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Drug Discovery & Development | 19/01/2026 | By News Bureau | 242
Russian Scientists Develop Chemical Method to Boost Anti-Cancer Drug Potency
Researchers in Russia have developed a novel chemical method that could significantly enhance the effectiveness of anti-cancer medicines, offering new momentum to oncology drug development.
Drug Discovery & Development | 16/01/2026 | By Darshana | 206
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy